This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Exforge HCT, amlodipin...
Budesonide, prolonged release tablets, 9 mg product- specific bioequivalence gui...
Human medicines European public assessment report (EPAR): Dafiro HCT, amlodipine...
Human medicines European public assessment report (EPAR): Exforge, amlodipine,va...
Human medicines European public assessment report (EPAR): Copalia, amlodipine,va...
Human medicines European public assessment report (EPAR): Dafiro, amlodipine,val...
Budesonide, gastro-resistant hard capsules, 3 mg, gastro- resistant granules, 9 ...
Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 ...
Human medicines European public assessment report (EPAR): Piqray, alpelisib, Dat...
Opinion/decision on a Paediatric investigation plan (PIP): Vaxzevria (previously...
Antimicrobial Sales and Use (ASU) Platform: Release notes
EMA Open Door Day, European Medicines Agency, Amsterdam, the Netherlands, from 9...
HMPC meeting report on European Union herbal monographs, guidelines and other ac...
Human medicines European public assessment report (EPAR): Duloxetine Viatris (pr...
Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir...
Human medicines European public assessment report (EPAR): Pemetrexed Fresenius K...
Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,av...
Human medicines European public assessment report (EPAR): Pemetrexed Accord, pem...
Agenda - European medicines agencies network strategy (EMANS) to 2028 - webinar
Nilotinib product-specific bioequivalence guidance
Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg pro...
Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance